All In Biotech

Drug Trial Radar · NCT01840605

A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis

A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis (Ketotifen Fumarate-controlled, Double-blind, Comparative Study)

Last checked: Nov 19, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 303 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

303

Actual

Start

Mar 2013

Primary completion

Nov 2013

Study completion Nov 2013

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Apr 26, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 7 years, up to 15 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to verify the non-inferiority of TAU-284 to ketotifen fumarate dry syrup in the change in the severity of pruritus after the treatment period.

Conditions

  • Dermatitis
  • Atopic

Interventions

  • Bepotastine besilateDrug

    Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day

  • ketotifen fumarateDrug

    Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Pruritus ScoreTime frame: Baseline and 2 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical Corporation Kojinkai Asanuma Dermatology Clinic

    Hokkaido, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.